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light of the higher antibiotic-resistance reported in bioﬁlm-
growing bacteria, our ﬁndings on the role of anaerobes in
the occluding process should be considered in selecting and
dosing antibiotics for the prophylaxis of biliary stent block-
age.
doi:10.1016/j.ijid.2008.05.150
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Can Expanded Treatment Slow the AIDS Epidemic?
The Public Health Perspective
N. Kumarasamy
YRGCARE,VHS, Chennai, India
The introduction of antiretroviral therapy has changed the
course of HIV disease by improving survival rates. But ART
has equal potential for prevention, since it reduces the HIV
RNA level and the probability of HIV transmission from an
infected person to their sexual partners. Currently NIH is
undertaking a large randomized clinical trial (HPNT052) in
serodiscordant couples to study the effect of antiretrovi-
ral therapy in preventing HIV transmission to their partner.
Although there have been no randomized controlled clini-
cal trials on the subject, antiretroviral drugs are currently
used in clinical practice for post-exposure prophylaxis after
inadvertent occupational exposure or after sexual exposure
to the virus. The success story in using antiretrovirals for
HIV prevention has been shown from trials involving Mother
to child HIV transmission interventions. Hence Can Expanded
Treatment through the Public Health approach slow the AIDS
Epidemic?
doi:10.1016/j.ijid.2008.05.151
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Can Expanded Treatment Slow the AIDS Epidemic?
The Behavioral Scientist’s View
K. Chillag
CDC, Atlanta, GA, USA
This presentation explores existing and potential behav-
ioral and social science contributions to consideration of
the impacts of expanded antiretroviral (ARV) scale-up on
the global HIV epidemic. Behavioral science literature com-
monly evaluates sexual behavior (‘‘risk compensation’’) and
medication adherence. While such analyses are critical to
evaluation of overall impact and will be reviewed here,
the presenter seeks to highlight approaches and empirical
research that set (and sometimes problematize) such typi-
cally individually-based approaches in their social, cultural,
political, economic, and human-rights/ethical contexts. It,
furthermore, brings behavioral and social science contri-
butions to bear on the critical question of: ‘‘how do we
deﬁne and measure success?’’ The presentation addresses
the ways in which interdisciplinary behavioral and social
science work can illuminate key questions about feasibility
and sustainability as well as ‘‘unintended consequences’’ of
these biomedical interventions on non-biomedical HIV pre-
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ention interventions and social and health systems. From
practical standpoint, such analyses can 1) assist identi-
cation of appropriate methods and criteria to evaluate
mpacts; 2) assist targeting and revision of patient and com-
unity educational materials and involvement strategies;
nd 3) aid development of uptake, retention and medica-
ion and general program adherence schemes that more
xplicitly address economic, cultural, and social barriers.
systematic analysis of lay media (primarily print sources)
bout recent ARV scale-up will be used as a case study
o demonstrate how social/behavioral science perspectives
ay shed light on popular conceptions of such programs and
echnologies, how scientiﬁc information is interpreted by
edia and the general public, and how consequential mis-
onceptions may arise. In the overall presentation, special
mphasis is placed on examination of approaches and per-
pectives that are likely to inform questions and solutions
elevant to both ARV treatment and biomedical prevention
echnologies under testing, particularly implementation of
RV pre-exposure prophylaxis.
oi:10.1016/j.ijid.2008.05.152
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.E. Grulich
National Centre in HIV Epidemiology and Clinical Research,
ydney, Australia
ackground: With the exception of male circumcision and
ome behavioural interventions, randomised controlled tri-
ls (RCTs) of HIV prevention interventions have reported
isappointing results. In this presentation, data on post-
xposure prophylaxis (PEP, the provision of anti-retrovirals
ARVs) after exposure to prevent HIV infection) and
re-exposure prophylaxis (Pre-EP, ARVs provided before
xposure to prevent infection) will be reviewed.
Methods: A guided literature review on the efﬁcacy,
ost-effectiveness, implementation policy and likely public
ealth impact of PEP and pre-EP was conducted.
Results: No RCTs examining the efﬁcacy of PEP were iden-
iﬁed. Nevertheless, a variety of animal and observational
vidence suggests that PEP prescribed within 72 hours of HIV
xposure is likely to substantially reduce the risk of HIV
ransmission. PEP use at the population level is generally
ot cost-effective, unless its use is highly targeted towards
he highest risk exposures. Despite these limitations, poli-
ies recommending PEP after sexual and other HIV exposures
xist in many settings. Although it is possible that post-
P may prevent cases of transmission, a substantial public
ealth impact on the HIV epidemic is unlikely. RCTs eval-
ating the efﬁcacy of Pre-EP are currently underway in a
umber of settings. Animal data strongly suggest that Pre-
P will need to consist of combinations of more than one
RV. The cost effectiveness of Pre-EP will depend strongly
n the risk setting. No locations were identiﬁed which cur-
ently recommend Pre-EP, and there has been little study of
he potential public health impact of this preventive inter-
ention.
Conclusion: PEP is being increasingly utilized as a form of
IV prevention, despite the lack of any efﬁcacy data from
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CTs. On the other hand, RCTs will soon establish whether
re-EP is an effective means of HIV prevention. If Pre-EP
s proven effective, there will be substantial challenges in
ormulating a policy framework to guide its use.
oi:10.1016/j.ijid.2008.05.153
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. Mayer
Brown University, Providence, RI, USA
he possibility that antiretroviral drugs may be useful for
IV prevention has been suggested by animal studies that
ave documented that if these medications are used before
r after a retroviral challenge, they can protect against
he development of HIV infection. Epidemiological stud-
es in HIV discordant couples suggest that individuals with
ower plasma RNA levels are less likely to transmit HIV to
heir sexual partners. These ﬁndings have lent support to
ew HIV prevention approaches that include the evalua-
ion of the use of pre- and post-exposure prophylaxis (PrEP
nd PEP) in high risk HIV-uninfected persons, and studies
f the use of antiretroviral drugs to lower plasma RNA in
eople who are in discordant couples, in order to decrease
he likelihood of HIV transmission. Questions that remain
o be addressed include whether the beneﬁts of decreas-
ng HIV transmission are offset by behavioral disinhbition,
rug toxicities, and costs. An additional set of important
onsiderations include the timing and duration of antiretro-
iral drug use and whether these compounds are best used
s topical microbicides applied to the cervicovagingal or
ectal mucosa, or whether oral chemoprophylaxis is more
ffective. Over the next few years, several thousand at risk
ersons will be evaluated in efﬁcacy trials to address the
ptimal uses of antiretroviral medications for HIV preven-
ion.
oi:10.1016/j.ijid.2008.05.154
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potted Group Rickettsioses in Asia
. Mediannikov ∗, I. Tarasevich
Gamaleya State Institute of Epidemiology and Microbiology,
oscow, Russia
ick-borne rickettsial diseases are usually called spotted
evers. Their agents, rickettsiae from spotted fever group
SFG), are obligate intracellular bacteria widespread in
ature and associated with parasitic blood-feeding arthro-
ods. Ixodid ticks are common human parasites and they
ay host different microbial pathogens that are often
ransmitted via ticks feeding on humans. Humans are not
atural hosts in rickettsial lifecycle, but due to high fre-
uency of tick bites, the incidence of tick-borne diseases,
ncluding rickettsiosis, may be very high. A vast Asiatic ter-
itory with different biotopes harbors lots of natural foci
f multiple tick species. For the moment, 9 rickettsial dis-
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ases are more or less regularly reported in Asia and 2
ore rickettsial species potentially associated with human
llnesses were found. Rickettsiae recognized as human
athogens are R.conorii indica, agent of Indian tick typhus
India), R.sibirica sibirica, agent of Siberian tick typhus
Eastern Russia, Mongolia, China), R. heilongjiangensis,
gent of Far Eastern tick-borne rickettsiosis (Eastren Rus-
ia, Nothern China), R. japonica, agent of Japanese spotted
ever (Japan, Korea), R.sibirica mongolitimonae (Nothern
hina), agent of LAR (Lymphangitis-associated rickettsio-
is), R.aeschlimannii, unnamed spotted fever (Kazakhstan),
. raoultii, unnamed rickettsiosis (Eastern Russia), R.honei,
hai tick typhus (Malaysia, Thailand, Laos) and Candidatus
ickettsia kellyi, unnamed rickettsiosis (India). Suggested
athogenicity were reported for R. helvetica found in Japan
nd R.tamurae (Japan, Laos). Studies show that in some
egions, the seropositivity rate for SFG is as high as 57%
or certain population groups. The real role of tick-borne
ickettsiosis in human pathology also may be shaded by lack
f diagnostic facilities and methods in some countries, mis-
iagnosing with scrub typhus, murine typhus, dengue fever
nd other clinically resembling entities.
oi:10.1016/j.ijid.2008.05.155
3.002
crub Typhus
. Suputtamongkol
Department of Medicine, Faculty of Medicine Siriraj Hospi-
al, Mahidol University, Bangkok, Thailand
crub typhus is recently recognized as a common cause of
cute fever in rural Asia. Clinical presentations of scrub
yphus vary widely from acute ﬂu-like syndrome, with or
ithout signs of organ dysfunction such as jaundice or renal
nsufﬁciency, to multi-organ dysfunction mimicking sepsis
yndrome. Acute undifferentiated fever (AUF) with or with-
ut organ dysfunction is the major clinical presentation of
crub typhus. The incidence of scrub typhus ranged from 1.1
o 19.3% in various studies conducted in indigenous patients
ho presented with AUF in rural hospitals in Malaysia,
ndonesia and Thailand. The incidence of scrub typhus,
urine typhus, and SFG rickettsioses was 7.8%, 2.4%, and
% respectively in a recent study conducted in patients with
UF who presented with severe manifestations in Thailand.
aundice, renal dysfunction, abnormal chest radiography on
dmission occurred in 21%, 35.7%, and 50% respectively in
atients with severe scrub typhus. Multiorgan dysfunction or
epsis occurred in 14%. Clinical spectrum of severe murine
yphus and SFG rickettsioses were similar to scrub typhus.
he reported mortality of severe scrub typhus varied from
.4%to 16.7%.
Awareness that scrub typhus is one of the common cause
f AUF in adults in rural Asia improves the probability of an
ccurate clinical diagnosis. Early recognition and appropri-
te treatment reduce morbidity and mortality. Results from
ecent clinical studies from Thailand indicate that rational
ntimicrobial therapy would be doxycycline in mild cases
nd a combination of either cefotaxime or ceftriaxone and
oxycycline in severe cases. Azithromycin could be consid-
red as an alternative treatment when ever doxycycline
